
    
The genomic variant c.5644C>A p.Arg1882= rs796053166 on the SCN2A gene is a synonymous variant, which means that it does not alter the amino acid sequence of the encoded protein. SCN2A encodes the alpha subunit of the voltage-gated sodium channel NaV1.2, which plays a critical role in the initiation and propagation of action potentials in neurons. This channel is essential for the proper functioning of the central nervous system and is implicated in a variety of epilepsy syndromes and related neurodevelopmental disorders.Despite being a synonymous variant, rs796053166 has been implicated in the clinical phenotype of epilepsy syndromes. Specifically, the variant has been associated with a spectrum of epilepsy phenotypes, including neonatal-infantile seizures and later-onset episodic ataxia [2]. The variant has been identified in patients presenting with neonatal-onset seizures that remit after several months, followed by the onset of episodic ataxia in early childhood [2]. This clinical presentation suggests that the variant may have functional consequences that contribute to neuronal hyperexcitability, even though it does not change the protein sequence.Electrophysiological studies have demonstrated that the mutation p.Arg1882Gly, which affects the same residue as the synonymous variant rs796053166, causes gain-of-function effects on NaV1.2 channels [2][7]. These effects include a hyperpolarizing shift of the activation curve and an increase in sodium current density, which are consistent with increased neuronal excitability and a predisposition to seizures [7]. Although the synonymous variant rs796053166 does not alter the amino acid sequence, it is possible that it could affect mRNA stability, splicing, or other regulatory mechanisms that influence the expression or function of the NaV1.2 channel.The SCN2A gene has been extensively studied, and more than 150 de novo missense mutations have been reported to date, many of which result in epilepsy and other neurodevelopmental disorders [1]. The variant rs796053166 is located in a region of SCN2A that has been described as a mutation hotspot, further supporting the potential clinical relevance of variants in this region [1].In summary, the SCN2A variant c.5644C>A p.Arg1882= rs796053166 is a synonymous variant that has been associated with epilepsy syndromes characterized by neonatal-infantile seizures and later-onset episodic ataxia. Although synonymous variants do not typically affect protein function directly, this variant may influence the expression or function of the NaV1.2 channel in ways that contribute to the pathophysiology of these disorders. ClinVar submissions for this variant include 9 pathogenic and 1 benign submission, indicating a potential role in disease but also highlighting the complexity of interpreting its clinical significance.

SCN2A遺伝子におけるゲノム変異c.5644C>A p.Arg1882= rs796053166は同義変異であり、これはコードされるタンパク質のアミノ酸配列を変化させないことを意味します。SCN2Aは電位依存性ナトリウムチャネルNaV1.2のαサブユニットをコードしており、このチャネルはニューロンにおける活動電位の開始と伝播において重要な役割を果たします。このチャネルは中枢神経系の適切な機能に不可欠であり、さまざまなてんかん症候群や関連する神経発達障害に関与しています。

同義変異であるにもかかわらず、rs796053166はてんかん症候群の臨床表現型に関連していることが示されています。具体的には、この変異は新生児期から乳児期にかけての発作や、後に発症する発作性運動失調症（エピソディックアタキシア）を含むてんかん表現型のスペクトラムと関連しています[2]。この変異は、新生児期に発症する発作が数か月後に寛解し、その後幼児期早期に発作性運動失調症が発症する患者で確認されています[2]。この臨床的な特徴は、タンパク質配列を変化させないにもかかわらず、この変異が神経の過剰興奮性に寄与する機能的な影響を持つ可能性を示唆しています。

電気生理学的研究では、同じ残基に影響を与える変異p.Arg1882Glyが、NaV1.2チャネルにおける機能獲得効果を引き起こすことが示されています[2][7]。これらの効果には、活性化曲線の過分極シフトやナトリウム電流密度の増加が含まれ、これらは神経の興奮性の増加と発作の素因と一致しています[7]。同義変異rs796053166はアミノ酸配列を変化させませんが、mRNAの安定性、スプライシング、またはNaV1.2チャネルの発現や機能に影響を与える他の調節メカニズムに影響を与える可能性があります。

SCN2A遺伝子は広範に研究されており、これまでに150以上の新生変異（de novo missense mutation）が報告されており、その多くがてんかんや他の神経発達障害を引き起こすことが知られています[1]。変異rs796053166は、SCN2Aの変異ホットスポットとして記述されている領域に位置しており、この領域の変異の潜在的な臨床的関連性をさらに支持しています[1]。

まとめると、SCN2A変異c.5644C>A p.Arg1882= rs796053166は、新生児期から乳児期にかけての発作と後に発症する発作性運動失調症を特徴とするてんかん症候群と関連する同義変異です。同義変異は通常、タンパク質機能に直接影響を与えませんが、この変異はNaV1.2チャネルの発現や機能に影響を与え、これらの障害の病態生理に寄与する可能性があります。この変異に関するClinVarの提出データには、9件の病原性と1件の良性の提出が含まれており、疾患における潜在的な役割を示唆するとともに、その臨床的意義を解釈する複雑さを浮き彫りにしています。
    
## References
- [1] Viswanathan LG et al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Schwarz N et al. (2016). "Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia." Journal of neurology, 263(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26645390/)
- [3] Menezes LFS et al. (2020). "Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review." Frontiers in pharmacology, 11() [PubMed](https://pubmed.ncbi.nlm.nih.gov/33013363/)
- [4] Berecki G et al. (2022). "Functional correlates of clinical phenotype and severity in recurrent SCN2A variants." Communications biology, 5(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/35637276/)
- [5] Mason ER et al. (2019). "Resurgent and Gating Pore Currents Induced by De Novo SCN2A Epilepsy Mutations." eNeuro, 6(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31558572/)
- [6] Lauxmann S et al. (2021). "Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1-Associated Episodic Ataxia and a Comprehensive Review of the Literature." Frontiers in neurology, 12() [PubMed](https://pubmed.ncbi.nlm.nih.gov/34566847/)
- [7] Saras A et al. (2016). "Seizure Suppression by High Temperature via cAMP Modulation in Drosophila." G3 (Bethesda, Md.), 6(10) [PubMed](https://pubmed.ncbi.nlm.nih.gov/27558668/)
- [8] Yang L et al. (2024). "Phase separation as a possible mechanism for dosage sensitivity." Genome biology, 25(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/38225666/)
- [9] Canavati C et al. (2024). "Using multi-scale genomics to associate poorly annotated genes with rare diseases." Genome medicine, 16(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/38178268/)
- [10] Encinas AC et al. (2020). "Variable patterns of mutation density among NaV1.1, NaV1.2 and NaV1.6 point to channel-specific functional differences associated with childhood epilepsy." PloS one, 15(8) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/32845893/)

    
## ClinVar Submissions
- **[RCV000189180](https://www.ncbi.nlm.nih.gov/clinvar/RCV000189180/)**: not provided
- **[RCV001281369](https://www.ncbi.nlm.nih.gov/clinvar/RCV001281369/)**: Developmental and epileptic encephalopathy, 11
- **[RCV000521033](https://www.ncbi.nlm.nih.gov/clinvar/RCV000521033/)**: not provided
- **[RCV001387542](https://www.ncbi.nlm.nih.gov/clinvar/RCV001387542/)**: Seizures, benign familial infantile, 3 (and 1 more)
- **[RCV002470897](https://www.ncbi.nlm.nih.gov/clinvar/RCV002470897/)**: Developmental and epileptic encephalopathy, 11
- **[RCV001200926](https://www.ncbi.nlm.nih.gov/clinvar/RCV001200926/)**: Episodic ataxia, type 9
- **[RCV001374453](https://www.ncbi.nlm.nih.gov/clinvar/RCV001374453/)**: Seizures, benign familial infantile, 3
- **[RCV003388934](https://www.ncbi.nlm.nih.gov/clinvar/RCV003388934/)**: Episodic ataxia, type 9
- **[RCV002350149](https://www.ncbi.nlm.nih.gov/clinvar/RCV002350149/)**: Inborn genetic diseases
- **[RCV003027509](https://www.ncbi.nlm.nih.gov/clinvar/RCV003027509/)**: Seizures, benign familial infantile, 3 (and 1 more)
- **[RCV002319457](https://www.ncbi.nlm.nih.gov/clinvar/RCV002319457/)**: Complex neurodevelopmental disorder

    